Over Kanseri Sistemik Tedavisinin Bugünü ve Geleceği

S. M. Temkin et al., "Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations".

M. Gina and N. Scholler, "Preventive Strategies in Epithelial Ovarian Cancer".

S. Bouberhan, L. Philp, S. J. Hill, L. Al-Alem and B. R. Rueda, "Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer".

L. A. Torre et al., "Ovarian cancer statistics, 2018".

J. Dauplat, G. L. Bou�dec, C. Pomel and C. Scherer, "Cytoreductive surgery for advanced stages of ovarian cancer".

B. G. B. Z. L. W. L. J. W. K. Behbakht, "PARP Inhibitors: Clinical Utility and Possibilities of Overcoming Resistance".

R. T. Penson et al., "Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial".

A. Oaknin et al., "Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety".

R. M. Wenham and C. McClung, "Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives".

K. V. Clark-Knowles, A. M. O’Brien and J. I. Weberpals, "BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer".

Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, 3rd, Bidzinski M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020;38(11):1164-74.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-64.

Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620-31.

Dizon DS. PARP inhibitors for targeted treatment in ovarian cancer. Lancet. 2017;390(10106):1929-30.

E. Hartnett, J. Knight, M. Radolec, R. J. Buckanovich, R. P. Edwards and A. Vlad, "Immunotherapy Advances for Epithelial Ovarian Cancer".

O. L. Saux, I. Ray‐Coquard and S. I. Labidi‐Galy, "Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer".

G. Bogani et al., "Immunotherapy for platinum-resistant ovarian cancer".

A. Varga et al., "Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.".

J. F. Liu et al., "Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers".

E. K. Lee et al., "Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial".

E. K. Lee et al.. "Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)". Elsevier BV. vol. 32. pp. 100546-100546. May. 2020. 10.1016/j.gore.2020.100546.

C. Bachmann. "New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review". Multidisciplinary Digital Publishing Institute. vol. 15. no. 22. pp. 5356-5356. Nov. 2023. 10.3390/cancers15225356.

J. Hamanishi et al.. "Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)". Lippincott Williams & Wilkins. vol. 39. no. 33. pp. 3671-3681. Nov. 2021. 10.1200/jco.21.00334.

K. R. Kalli et al., "Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients".

Q. Guo, Q. Yang, J. Li, G. Liu, I. Nikoulin and S. Jia, "Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer".

Q. Xin, Y. Chen, X. Sun, R. Li, Y. Wu and X. Huang, "CAR-T therapy for ovarian cancer: Recent advances and future directions".

M. Kobayashi et al., "The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer".

X. Zhang, Y. Wu, T. Xu and M. Cui, "CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy".

L. E. Kandalaft, D. J. Powell, N. Singh and G. Coukos, "Immunotherapy for Ovarian Cancer: What's Next?".

N. G. Nwani, L. E. Sima, W. Nieves‐Neira and D. Matei. "Targeting the Microenvironment in High Grade Serous Ovarian Cancer". Multidisciplinary Digital Publishing Institute. vol. 10. no. 8. pp. 266-266. Aug. 2018. 10.3390/cancers10080266.

B. Roane et al.. "Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma". American Association for Cancer Research. vol. 20. no. 3. pp. 602-611. Mar. 2021. 10.1158/1535-7163.mct-20-0412.

M. Abreu et al.. "Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer". Multidisciplinary Digital Publishing Institute. vol. 9. no. 5. pp. 1218-1218. May. 2020. 10.3390/cells9051218.

X. Chu et al.. "Human antibodies targeting ENPP1 as candidate therapeutics for cancers". Frontiers Media. vol. 14. Jan. 2023. 10.3389/fimmu.2023.1070492.

A. M. Saleh and R. Perets, "Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy".

A. Skorda, M. L. Bay, S. Hautaniemi, A. Lahtinen and T. Kallunki. "Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises". Multidisciplinary Digital Publishing Institute. vol. 14. no. 24. pp. 6257-6257. Dec. 2022. 10.3390/cancers14246257.

S. M. Temkin et al., "Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations".

M. Gina and N. Scholler, "Preventive Strategies in Epithelial Ovarian Cancer".

S. Bouberhan, L. Philp, S. J. Hill, L. Al-Alem and B. R. Rueda, "Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer".

L. A. Torre et al., "Ovarian cancer statistics, 2018".

J. Dauplat, G. L. Bou�dec, C. Pomel and C. Scherer, "Cytoreductive surgery for advanced stages of ovarian cancer".

B. G. B. Z. L. W. L. J. W. K. Behbakht, "PARP Inhibitors: Clinical Utility and Possibilities of Overcoming Resistance".

R. T. Penson et al., "Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial".

A. Oaknin et al., "Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety".

R. M. Wenham and C. McClung, "Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives".

K. V. Clark-Knowles, A. M. O’Brien and J. I. Weberpals, "BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer".

Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, 3rd, Bidzinski M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020;38(11):1164-74.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-64.

Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620-31.

Dizon DS. PARP inhibitors for targeted treatment in ovarian cancer. Lancet. 2017;390(10106):1929-30.

E. Hartnett, J. Knight, M. Radolec, R. J. Buckanovich, R. P. Edwards and A. Vlad, "Immunotherapy Advances for Epithelial Ovarian Cancer".

O. L. Saux, I. Ray‐Coquard and S. I. Labidi‐Galy, "Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer".

G. Bogani et al., "Immunotherapy for platinum-resistant ovarian cancer".

A. Varga et al., "Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.".

J. F. Liu et al., "Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers".

E. K. Lee et al., "Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial".

E. K. Lee et al.. "Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)". Elsevier BV. vol. 32. pp. 100546-100546. May. 2020. 10.1016/j.gore.2020.100546.

C. Bachmann. "New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review". Multidisciplinary Digital Publishing Institute. vol. 15. no. 22. pp. 5356-5356. Nov. 2023. 10.3390/cancers15225356.

J. Hamanishi et al.. "Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)". Lippincott Williams & Wilkins. vol. 39. no. 33. pp. 3671-3681. Nov. 2021. 10.1200/jco.21.00334.

K. R. Kalli et al., "Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients".

Q. Guo, Q. Yang, J. Li, G. Liu, I. Nikoulin and S. Jia, "Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer".

Q. Xin, Y. Chen, X. Sun, R. Li, Y. Wu and X. Huang, "CAR-T therapy for ovarian cancer: Recent advances and future directions".

M. Kobayashi et al., "The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer".

X. Zhang, Y. Wu, T. Xu and M. Cui, "CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy".

L. E. Kandalaft, D. J. Powell, N. Singh and G. Coukos, "Immunotherapy for Ovarian Cancer: What's Next?".

N. G. Nwani, L. E. Sima, W. Nieves‐Neira and D. Matei. "Targeting the Microenvironment in High Grade Serous Ovarian Cancer". Multidisciplinary Digital Publishing Institute. vol. 10. no. 8. pp. 266-266. Aug. 2018. 10.3390/cancers10080266.

B. Roane et al.. "Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma". American Association for Cancer Research. vol. 20. no. 3. pp. 602-611. Mar. 2021. 10.1158/1535-7163.mct-20-0412.

M. Abreu et al.. "Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer". Multidisciplinary Digital Publishing Institute. vol. 9. no. 5. pp. 1218-1218. May. 2020. 10.3390/cells9051218.

X. Chu et al.. "Human antibodies targeting ENPP1 as candidate therapeutics for cancers". Frontiers Media. vol. 14. Jan. 2023. 10.3389/fimmu.2023.1070492.

A. M. Saleh and R. Perets, "Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy".

A. Skorda, M. L. Bay, S. Hautaniemi, A. Lahtinen and T. Kallunki. "Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises". Multidisciplinary Digital Publishing Institute. vol. 14. no. 24. pp. 6257-6257. Dec. 2022. 10.3390/cancers14246257.